Research Article
Comparison of Clinical Features between the High and Low Serum KL-6 Patients with Acute Exacerbation of Interstitial Lung Diseases
Table 1
Patients’ characteristics.
| Characteristics | High serum KL-6 (N = 38) | Low serum KL-6 (N = 57) | Total patients (N = 95) | P values (high KL-6 vs. low KL-6) |
| Age, y | 75 (71–80) | 76 (70–81) | 75 (71–80) | 0.761 | Male sex | 24 (63) | 44 (77) | 68 (72) | 0.137 | CCIS | 2 (1–4) | 2 (1–4) | 2 (1–4) | 0.832 | From symptom onset to treatment, days | 7 (2.5–19) | 6 (2.5–14) | 6 (2.8–15) | 0.840 |
| Diagnosis of AE | Idiopathic ILDs | | | | | IPF | 8 (21) | 9 (16) | 17 (18) | 0.589 | Others | 20 (53) | 25 (44) | 45 (47) | 0.412 | Secondary ILDs | | | | | CTD-ILD | 6 (16) | 13 (23) | 19 (20) | 0.445 | Drug | 3 (8) | 10 (17) | 13 (14) | 0.232 | Others | 1 (2) | 0 (0) | 1 (1) | 0.400 |
| Biomarkers | P/F ratio | 274 (218–308) | 248 (152–311) | 268 (187–309) | 0.329 | LDH, IU/L | 321 (268–446) | 277 (216–375) | 282 (235–405) | 0.013 | SP-D, ng/mL | 337 (137–541) | 207 (140–364) | 233 (138–409) | 0.112 |
| HRCT scores | GGO scores | 10 (6–13.8) | 10 (8–15.5) | 10 (7–15) | 0.729 | Honeycomb | 3 (0–7) | 0 (0–4) | 1 (0–5) | 0.045 |
| Treatment | PSL before pulse | 11 (29) | 10 (18) | 21 (22) | 0.189 | PSL pulse | 38 (100) | 57 (100) | 95 (100) | 1.000 | PSL after pulse | 11 (29) | 23 (40) | 34 (36) | 0.256 | Macrolide | 8 (21) | 12 (21) | 20 (21) | 1.000 | NEI | 3 (8) | 8 (14) | 11 (12) | 0.360 | Anticoagulant | 6 (16) | 12 (21) | 18 (19) | 0.521 |
| Outcome | Six-month mortality | 12 (32) | 15 (26) | 27 (28) | 0.685 |
| Cause of mortality | AE | 11 (29) | 14 (25) | 25 (26) | 0.634 | Lung cancer | 1 (3) | 1 (2) | 2 (2) | 0.771 |
|
|
Results are shown as medians with 25th–75th percentiles or numbers (%). Serum SP-D could be measured in 92 patients (97%). AE: acute exacerbation; CCIS: Charlson Comorbidity Index score; CVD-IP: collagen vascular disease-related interstitial pneumonia; GGO: ground-glass opacity; HRCT: high-resolution computed tomography; ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; KL-6: Krebs von den Lungen-6; LDH: lactate dehydrogenase; NEI: neutrophil elastase inhibitor; P/F ratio: partial pressure of oxygen in arterial blood/fraction of the inspiratory oxygen; PSL: prednisolone; SP-D: surfactant protein-D.
|